4285. Package # 250 (Cervical screening, COTESTING: Liquid-based cytology PAP test (BD SurePath technology, FDA approved). CYTOLOGICAL PASSPORT (BD FocalPoint technology, FDA approved) and PCR. HPV HCR 14 (cobas HPV FDA approved).
Number of tests: 2
Liquid-based cytology PAP test (BD SurePath technology, FDA approved). CYTOLOGICAL PASSPORT (BD FocalPoint technology, FDA approved).
PCR. HPV HCR 14 (cobas HPV FDA approved). Genotyping 16 and 18 and groups 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 (u/g scrape, qualitative)
Turnaround time (days): 3
1610 ₴
Important information
* TEST FOR WOMEN ONLY
Description
Package No. 250 – a comprehensive cervical examination combining a Pap test using liquid-based cytology (BD SurePath), Cytology Passport (BD FocalPoint GS Imaging System), and PCR. HPV HR 14 types.
Provides maximum sensitivity and accuracy through the combination of liquid-based cytology, artificial intelligence, and HPV testing for 14 oncogenic virus types. Complies with the requirements of Order of the Ministry of Health No. 1057 and international cervical cancer screening standards.
Learn more about the technology and the Cytological Passport.
When and who needs the test?
- As primary screening for women aged 25 and older once every 5 years, according to Order of the Ministry of Health of Ukraine No. 1057
- For women with abnormal Pap test results (ASC-US, LSIL, HSIL)
- In cases of suspected HPV-associated changes
- After CIN treatment or conization
- For monitoring treatment effectiveness
Biological material
- Site-specific scrapings collected depending on the test
Preparation for cytology
- Collect the material before starting treatment with antibacterial/antifungal drugs (general and local action).
- In case of treatment monitoring – 14 days after the end of the course of treatment with antibacterial/antifungal drugs.
- Avoid sexual intercourse for 3 days.
- Exclude douching and the use of vaginal...